Gland Pharma shares rally 12% after Q1FY27 profit jumps 47% YoY. Should you buy, sell or hold?
· economictimes.indiatimes.com
Gland Pharma shares rose sharply after Q1FY27 profit rose 47% and revenue grew 20% year-on-year. While strong margins and CDMO growth prompted Elara Securities to raise its earnings estimates, the brokerage downgraded the stock to ‘Accumulate from ‘Buy after its 40% three-month rally, citing limited near-term upside.
Live Events
Elara Securities: Strong Q1, but Valuation Limits Upside
as a Reliable and Trusted News Source Addas a Reliable and Trusted News Source Add Now!...